Worlds First Affordable In-House Stem Cell Procedure Kit

What is stem cell therapy? Stem cells are the bodys repair cells. They have the ability to divide and differentiate into many different types of cells based on where they are needed throughout the body. Stem cells can divide and turn into tissues such as skin, fat, muscle, bone, cartilage, and nerve to name a few. They even possess the ability to replicate into organs such as the heart, liver, intestines, pancreas, etc.

What are the different types of stem cells? There are two basic types of stem cells; embryonic and somatic (adult). Embryonic stem cells are found in the placenta and embryo. These cells are called totipotent, which means they have the ability to reproduce into any mature cell type. While embryonic stem cells offer the greatest potential in healing, there are obviously moral and ethical concerns in harvesting these cells.

The second type of stem cell is the adult stem cell. These stem cells are called multipotent, which means they can differentiate into closely related cell lines, but they are not capable of creating a complete organ. Adult stem cells are found in the bone marrow, adipose tissue (fat), skin, liver, blood vessels, and neurons. Contrary to embryonic stem cells, there are no moral or ethical concerns in harvesting these cells, activating them, and reintroducing them back to the patient in areas where healing and regeneration is needed.

So why do we take the cells from adipose (fat) tissue? Adult stem cells are highly concentrated in the fat tissue. There are 50 to 1,000 times more stem cells in the fat than the bone marrow. At this concentration, it is no longer necessary to culture the stem cells to acquire the necessary cell numbers to make a healing impact. The procedure to extract fat from the patient is much quicker and less invasive than a spay. The stem cells are contained within a pool of cells in the fat termed the Stromal Vascular Fraction (SVF). The SVF may impart anti-inflammatory effects, add bioactive peptides, and contribute to reformation and architectural organization. These are benefits lost once stem cells are cultured.

So what can we do with the stem cells? Adult stem cells are capable of dividing into many different cell types. With this capability, we can use them as a treatment for joint injuries, ligament and tendon damage, and fractured bones. Research and clinical trials currently support the use of stem cells in these conditions. Ongoing research is targeting other areas of the body for treatment and the preliminary results are very encouraging.

So what makes MediVet Americas technology better? With our patented LED technology and by incorporating Platelet-Rich Plasma (PRP) the same treatment used by many sports professionals, Veterinary Stem Cell, Stem Cell Therapy for Pets, Adipose Stem Cell Therapy, Platelet Rich Plasma Horses, Adipose Stem Cell Treatment, Platelet Rich Plasma Dogs is able to acquire the most living stem cells of any company currently offering this technology. If your beloved pet is going to have to endure the surgical procedure, we want to make sure they are going to get the most out of it! Veterinary Stem Cell, Stem Cell Therapy for Pets, Adipose Stem Cell Therapy, Platelet Rich Plasma Horses, Adipose Stem Cell Treatment, Platelet Rich Plasma Dogs also offers Cryobanking, where you can store extra cells from the procedure for future use.

So how will the procedure work? The day of the procedure, the veterinarian will anesthetize your pet. They will surgically remove a couple tablespoons of fat. This is a quick and simple procedure that is generally easier than performing a spay. They will then process the fat to remove the stem cells. Processing generally takes a couple of hours. After the stem cells have been collected, your pet will generally be sedated and the stem cells will be administered into the affected joints and/or into the bloodstream. It is important that you do not feed your pet the night before the procedure.

When will I see results? We expect you to see results! While we know every animal is different and there are no guarantees, we have seen positive clinical improvement in 95% of the arthritic cases performed nationwide. Some owners have even reported seeing a difference in as little as a week! While quick results are possible, we expect you to begin seeing improvement within the first 90 days following treatment. Really bad arthritis may require multiple injections, so banking your extra cells is always a good idea!

Is this procedure safe? As with any procedure that involves anesthesia, there is always a risk. However, the stem cells are coming from your pet and are being re-administered back to your pet. There is no risk of an allergic reaction. In rare casesthere might be a mild immune reaction in the injected joint that should subside within a day or two.

Read more from the original source:
Pet Stem Cell Therapy | StemCell Therapy MD

Dr. Nazareth #39;s Experience with Veterinary Stem Cells
Watch veterinarian Dr. Darrell Nazareth discuss the advantages of animal stem cell treatment provided by StemLogix. The cutting-edge technology developed by Stemlogix helps treat injured or aging animals in the quickest and most affordable way possible. Dr. Nazareth explains the key differences between StemLogix and other veterinary applications of animal stem cell therapy, such as the expedited service StemLogix administers. Dr. Nazareth illustrates the efficiency of the StemLogix system comparing the cost and time using an off-site laboratory, as opposed to the in-house delivery of viable pet stem cells in just one procedure. To learn more about pet stem cell therapy and its many applications including pet arthritis, visit: stemlogix.com StemLogix LLC Telephone: 954.260.7118 1640 Sweetgum Terrace Weston, Florida 33327 Email: info@stemlogix.comFrom:StemLogixLLCViews:106 0ratingsTime:05:49More inPets Animals

More:
Dr. Nazareth's Experience with Veterinary Stem Cells - Video

StemLogix: Revolutionary Animal Stem Cell Therapy
StemLogix, developer of the pioneering in-clinic animal stem cell therapy solutions, exceeds the standard for delivery and application of veterinary regenerative medicine. Watch veterinarians Dr. Dennis Vrooman, Dr. David Laurence, and Dr. Sean Back of Beach Pet Hospital discuss how StemLogix #39;s revolutionary new method of stem cell treatments for suffering animals and pets. The veterinarians of Beach Pet Hospital reveal and demonstrate the process and application of veterinary stem cell treatments for dogs, cats, and horses, highlighting the efficiency and cost effectiveness of utilizing in-house laboratory techniques. StemLogix trains veterinarians how to create viable doses of pet stem cells on location and supplies all necessary equipment for successful stem cell extraction. From harvesting, cultivating, then reintroducing animal stem cells occurs within one veterinary procedure, saving time, money, and preventing undue stress for both patient and owner. Therapeutic veterinary stem cell can be used in a great number of applications such as arthritis, joint problems or disease, ligament damage, and elbow or hip dysplasia in animals and pets. StemLogix offers a safe and natural option to relieving pain and mobility issues within pets as opposed to medication and supplements. To learn more about animal and pet stem cell therapy and veterinary regenerative medicine, visit: stemlogix.com StemLogix LLC Telephone: 954.260.7118 1640 Sweetgum Terrace Weston, Florida 33327 Email ...From:StemLogixLLCViews:497 0ratingsTime:04:43More inPets Animals

Continued here:
StemLogix: Revolutionary Animal Stem Cell Therapy - Video

MADISON, Wis., Oct. 3, 2012 /PRNewswire/ --Novelos Therapeutics, Inc. (NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that an oral presentation on research conducted by Jamey Weichert, Ph.D., Lance Hall, M.D., Anne M. Traynor, M.D., Glenn Liu, M.D. and their colleagues is being made by Dr. Weichert at the Imaging in 2020 Conference taking place September 30 to October 4, 2012 in Jackson Hole, Wyoming. This presentation describes the mechanistic foundation for Novelos' diapeutic (diagnostic + therapeutic) technology platform together with animal data and initial findings in advanced cancer patients that demonstrate selective and prolonged uptake of Novelos' PET imaging I-124-CLR1404 (LIGHT), therapeutic I-131-CLR1404 (HOT) and optical imaging CLR1502 (GLOW2) compounds in a range of tumor types. Dr. Weichert is Associate Professor of Radiology, Dr. Hall is Assistant Professor of Radiology, Dr. Traynor is Associate Professor of Medicine and Dr. Liu is Associate Professor of Medicine, all in the School of Medicine and Public Health at the University of Wisconsin, Madison and all are members of the UW Carbone Cancer Center. Dr. Weichert is also the Chief Scientific Officer of Novelos and the founder of Novelos' technology.

"LIGHT, HOT and GLOW2 were designed to exploit a common feature of most, if not all cancer cells including cancer stem cells that results in their selective uptake and retention in a wide range of malignant tumors compared with normal tissues," said Dr. Weichert. "By incorporating a unique functional property in each, we have generated an array of potential products that could, singly and in combinations, significantly improve the detection and treatment of cancer in multiple ways."

Slides of the oral presentation are available at http://www.novelos.com/technology-ip/posters-publications/

In the presentation, titled Molecular Diapeutics: Phospholipid Ether Analogs as Broad-Spectrum Cancer and Cancer Stem Cell Detection and Treatment, Dr. Weichert presents data showing that LIGHT, HOT and GLOW2 all share a common cancer-targeted core chemical structure. Each attaches a unique moiety to this delivery vehicle LIGHT a PET imaging agent (iodine-124), HOT a radiotherapeutic agent (iodine-131) and GLOW2 an optical imaging agent (near-infrared tracer). Results described with LIGHT demonstrate broad-spectrum tumor PET imaging in dozens of animal tumor models, and recent human findings in ongoing Phase 1-2 clinical trials show selective uptake and retention by primary tumors and metastases in advanced non-small cell lung and brain cancer patients. HOT results shown include single-dose efficacy in a wide range of animal tumor models as well as selective uptake and retention in cancerous tumors in clinical trials to date. The presentation highlights the potential diapeutic application of LIGHT and HOT, based on their chemical identity, to provide individualized treatment to cancer patients. For example, LIGHT serves as an ideal biomarker to potentially identify patients most likely to benefit from therapy with HOT. Dr. Weichert's talk also describes how selective uptake of GLOW2 could provide better definition of tumor margins in real time during cancer surgery, enabling more complete and selective removal of malignant tissue and potentially improving patients' prognosis. Data illustrating the potential use of GLOW2 for non-invasive detection of tumors is also being shown.

"We are pleased to share the science behind Novelos' cancer-targeted diapeutic platform with the scientific community attending this prestigious conference," said Harry Palmin, President and CEO of Novelos. "As we have recently reported, we continue to make good clinical progress with LIGHT and HOT across multiple human trials while advancing GLOW2 towards human trials."

About Novelos Therapeutics, Inc.

We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (LIGHT) is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the third quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding. CLR1502 (GLOW2) is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit http://www.novelos.com

INVESTOR CONTACTS

J. Patrick Genn, Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com

Anne Marie Fields, Senior Vice President, LHA, Ph: (212) 838-3777, Email: afields@lhai.com, @LHA_IR_PR

Read the original post:
Novelos Therapeutics and Academic Collaborators Present Diapeutic Technology Platform at Imaging in 2020 Conference

MADISON, Wisc., Oct. 2, 2012 /PRNewswire/ --Novelos Therapeutics, Inc. (NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, President and CEO of Novelos, will present a corporate update at the 11th Annual BIO Investor Forum on Wednesday, October 10, 2012. Mr. Palmin is scheduled to present at 2:30pm PT in the Sea Cliff room. The conference will take place October 9-10 at the Palace Hotel in San Francisco.

A live webcast of the Novelos presentation may be accessed via http://www.novelos.com

The webcast will be archived for 90 days following the presentation.

The BIO Investor Forum is an international investor conference featuring leading private and emerging public biotech companies. Information about the conference is available at http://www.bio.org/events/conferences/11th-annual-bio-investor-forum

About Novelos Therapeutics, Inc.We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. Our cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (LIGHT) is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent. We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the third quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding. CLR1502 (GLOW2) is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit http://www.novelos.com

INVESTOR CONTACTSJ. Patrick Genn, Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com

Anne Marie Fields, Senior Vice President, LHA, Ph: (212) 838-3777, Email: afields@lhai.com, @LHA_IR_PR

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

Read the original:
Novelos Therapeutics to Present at 11th Annual Bio Investor Forum on October 10

Animal Cell Therapies, Inc., a veterinary regenerative therapies company, is announcing the commitment of $1.5 million to develop a proprietary line of canine orthopedic products called PROTECT.

SAN DIEGO, CA (PRWEB) September 28, 2012

"This type of financial commitment demonstrates that we are dedicated to propelling innovation and providing solutions for veterinarians, pets and pet owners, said Dr. Kathy Petrucci, Chief Medical Officer of Animal Cell Therapies.

The dedicated funds will allow Animal Cell Therapies, in partnership with leading researchers, to fully develop the PROTECT Cell Therapy product portfolio. The portfolio will include a proprietary cell processing procedure, patented materials, precise protocols and an all-inclusive operating system.

We believe R&D capital allocated to strategic partnerships is a necessary step towards commercialization. said Adam Irving, Chief Executive Officer of Animal Cell Therapies.

About Animal Cell Therapies

Founded in January 2009 in San Diego, California, Animal Cell Therapies (ACT) is the manifestation of veterinarian, Dr. Kathryn Petrucci, whose vision is to improve the lives of animals through thoughtful research and development, innovation and strategic partnerships. At the Companys California-based stem cell research and development facility, the ACT team is focused on developing and delivering revolutionary cellular treatment and services to their customers. For more information, visit http://www.actcells.com.

Preston Munsch Animal Cell Therapies, Inc. (858) 678-8843 Email Information

More here:
Animal Cell Therapies Announces $1.5 million Developmental Work in Canine Orthopedic Product Line

(WGBA/NBC) - It is a story that gives hope to pet owners all over the country stem cell therapy for animals suffering from problems like arthritis or hip displaysia.

Stem cells are taken out of the dog's fatty tissue are harvested then injected into problem areas leaving the dogs completely healed.

"We couldn't take him on walks, he just laid around a lot," said Keith Nosowiak, Deniro's owner.

"We'd hear whimpering overnight, she'd take a few steps and she would sit down," said Luther Kortbein, Shadow's owner.

Until two months ago, Deniro suffered from severe arthritis, Shadow from hip displaysia.

Deniro's owner thought he may even have to put his German shepherd down.

"We felt we had a decision to make with his quality of life and being in pain we didn't want him to be in pain," Noskowiak said.

Shadow's owner was willing to try anything to cure her.

"Whatever the cost needed to get this done we were willing to do," Kortbein said.

Then Packerland Veterinary Center offered them stem cell therapy by using the dogs own stem cells and then injecting them back into the bloodstream joints.

View post:
Stem cells revolutionizing veterinary medicine

MADISON, Wis., June 27, 2012 /PRNewswire/ --Novelos Therapeutics, Inc. (NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present a corporate update at the LHA Life Sciences & Medical Technologies Virtual Conference on Thursday, June 28, 2012. Mr. Palmin is scheduled to present at 12:30 p.m. Eastern time.

A webcast of the Novelos presentation may be accessed at http://www.novelos.com

The webcast will be archived for 90 days following the presentation.

This day-long virtual conference event includes 30-minute presentations with accompanying slides from seven industry leaders, and begins at 9:00 a.m. Eastern time. The event may be accessed at the PrecisionIR event site http://www.vcall.com/CustomEvent/lipper/index.asp

About Novelos Therapeutics, Inc.

We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. Our three cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (LIGHT) is a small-molecule cancer-targeted PET imaging agent. We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the first quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need. CLR1404 (COLD), a pre-clinical cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition. Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit http://www.novelos.com

INVESTOR CONTACTS

J. Patrick Genn, Vice President of IR

Anne Marie Fields, Senior Vice President

Novelos Therapeutics, Inc.

Read more from the original source:
Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28

The United States' highest court is about to decide if a universal health care system will be introduced in the country. For families like the Ritters, the ruling will determine how they live the rest of their lives.

Anyone who knows the Ritter family's story might be surprised by how idyllic their house looks. They live in a new neighborhood on the outskirts of a town called Manheim in south-eastern Pennsylvania, occupying a two-story house with a light-brown wooden facade typical for this area. A gray station wagon stands in the driveway; roses and chamomiles decorate the entrance. The family's pet dog, a poodle named Bailey, plays outside. The air smells like freshly mown grass and freshly baked cookies.

Stacie and Benjamin Ritter live here with their four children: Abby, Ethan and twins Madeline and Hannah. The twins are identical but have completely different personalities. "I am the hippie," says outgoing, talkative Madeline. She is dressed in a linen skirt and wooden jewelry. In her spare time she paints pictures and makes earrings. Hannah, meanwhile, is shy and reserved. She wears black eyeliner and writes short stories about vampires and werewolves. "Hannah is a bit of a goth," says Madeline of her sister.

Hannah and Madeline are two typical American teenagers - but they have already lived through a lot more than most other 14-year-olds. When they were four they both developed a rare form of leukemia. They spent eight months in hospital fighting for their lives before a suitable stem cell donor was found in Germany. But they are still not healthy. "The treatment doesn't end when you leave the hospital," explains Stacie.

The cancer therapy stunted the girls' growth. They are smaller than their female classmates and only a few centimeters taller than their sister Abby, who is five years younger. Their survival still depends on expensive medication.

Hannah und Madeline survived cancer, but the therapy is barely affordable

The burden of pre-existing conditions

The twins were lucky to survive cancer, but in the current US health care system they are classified as high-risk patients. The term "pre-existing condition" hangs over them like a dark shadow. For a long time, American health insurance companies did not accept patients who had suffered from serious illness prior to applying for health insurance, or they offered them unaffordable premiums.

President Barack Obama's health care reform plan prohibits this kind of discrimination in the case of children, and it is set to include adults from 2014 onwards. But if the US Supreme Court rejects the reform, the Ritter twins' history of cancer could become their downfall. This could happen if their father lost his job and with it the family's health insurance - but even without this misfortune they would inherit the burden on becoming adults.

"We're talking about thousands of dollars in premiums," says Stacie. She sits at the dining table, speaking slowly as she recalls her daughters' illness and their health insurance struggle. Her words reveal a deep disappointment with her country's health care system. The leukemia treatment resulted in $30,000 in debts for the family. Half a year after the twins were diagnosed with the illness the family had to declare insolvency.

Originally posted here:
US Supreme Court to decide on health care reform

MADISON, Wis., June 19, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that the University of Wisconsin Carbone Cancer Center (UWCCC), a leading oncology research institution, has successfully dosed three patients in a Phase 1-2 positron emission tomography (PET) imaging trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging agent, in patients with primary or metastatic brain cancer. The three glioma patients were dosed with LIGHT at 5 mCi. Details of the trial design are available at http://www.clinicaltrials.gov ID: NCT01540513, or at http://www.novelos.com in the 'Clinical Trials' section. Lance Hall, M.D., is the trial's principal investigator. This trial is being funded by the UWCCC and the Institute for Clinical and Translational Research (ICTR). Detailed trial results are expected to be presented at a scientific venue at a later date.

"Despite recent advances in diagnostic and therapeutic techniques, prognosis of patients with many brain tumors, and particularly malignant gliomas, remains dismal. This reflects in part the diagnostic uncertainty in identifying infiltrative tumor growth of malignant gliomas which in turn affects subsequent treatment strategies," said Dr. Hall. "The preliminary results from these three glioma patients are very encouraging. We see strong and sustained uptake of LIGHT in cancerous tumors against very low background and have not observed any adverse safety signals. Interestingly, LIGHT's cancerous tumor to normal tissue uptake ratio exceeded 30:1 in one tumor, which compares favorably with PET agents that are generally considered good tumor biomarkers if tumor to normal tissue uptake ratios are in the range of 3:1 and 5:1."

"Having observed well-tolerated cancer-specific uptake with LIGHT at 5 mCi in three glioma patients, we look forward to evaluating more patients at this dose level in this indication," said Kim Hawkins, Vice President of Clinical Development of Novelos.

"We are very pleased by both the positive initial LIGHT imaging data in brain cancer patients obtained to date, and our continuing collaboration with the UWCCC," said Harry Palmin, President and CEO of Novelos. "We believe these results begin to establish proof-of-concept for LIGHT as a PET imaging agent for brain cancer, and could be used to calculate effective doses for Phase 2 clinical trials of I-131-CLR1404 (HOT) in this indication. HOT is our chemically identical small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells."

About LIGHT

LIGHT is a small molecule imaging agent that we believe has first-in-class potential for selective detection of tumors and metastases in a broad range of cancers. LIGHT is comprised of a small, non-pharmacological quantity of CLR1404 (COLD, acting as a cancer-targeted delivery and retention vehicle) labeled with the short-lived radioisotope, iodine-124, a new PET imaging isotope. PET imaging used in conjunction with CT scanning has now become the imaging method of choice in oncology. In studies to date, LIGHT selectively illuminated malignant tumors in 52 of 54 animal models of cancer, demonstrating broad-spectrum, cancer-selective uptake and retention. Investigator-sponsored Phase 1-2 trials of LIGHT as a PET imaging agent are ongoing. The trials include lung cancer, brain cancer and, starting in the third quarter of 2012, other solid tumors. These human trials, if successful, would likely provide proof-of-concept for LIGHT as a PET imaging agent with the potential to supplant the current "gold standard" agent, 18F-fluoro-deoxyglucose (FDG), due to what we believe to be LIGHT's superior cancer-specificity and more favorable logistics of clinical use. Also, tumor uptake data would likely accelerate clinical development of HOT by predicting efficacy and enabling calculation of efficacious doses of HOT for Phase 2 trials.

About the UW Carbone Cancer Center in Madison

The UWCCC is recognized throughout the nation as one of the leading innovators in cancer research, quality patient care and active community involvement. It is the only comprehensive cancer center, as designated by the National Cancer Institute, in Wisconsin. An integral part of the UW School of Medicine and Public Health, the UWCCC unites physicians and scientists who work together in translating discoveries from research laboratories into new treatments that benefit cancer patients. To learn more about clinical studies and other initiatives, visit http://www.uwhealth.org/uw-carbone-cancer-center/for-researchers/uwccc/28373

About Novelos Therapeutics, Inc.

We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. Our three cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (LIGHT) is a small-molecule cancer-targeted PET imaging agent. We believe LIGHT has first-in-class potential and Phase 1-2 clinical trials are ongoing. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential. HOT Phase 1b dose-escalation trial is ongoing and we expect HOT to enter Phase 2 trials in the first quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need. CLR1404 (COLD), a pre-clinical cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition. Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way. For additional information please visit http://www.novelos.com

Go here to see the original:
Novelos Therapeutics Announces Positive Initial Imaging Results In Brain Cancer Trial With I-124-CLR1404 (LIGHT ...